JP2021102620A - 乾燥粉末配合および使用方法 - Google Patents
乾燥粉末配合および使用方法 Download PDFInfo
- Publication number
- JP2021102620A JP2021102620A JP2021035890A JP2021035890A JP2021102620A JP 2021102620 A JP2021102620 A JP 2021102620A JP 2021035890 A JP2021035890 A JP 2021035890A JP 2021035890 A JP2021035890 A JP 2021035890A JP 2021102620 A JP2021102620 A JP 2021102620A
- Authority
- JP
- Japan
- Prior art keywords
- inhalation
- dry
- particles
- less
- dry powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 title claims abstract description 192
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- 238000000034 method Methods 0.000 title claims description 113
- 238000009472 formulation Methods 0.000 title description 21
- 239000002245 particle Substances 0.000 claims abstract description 298
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims abstract description 189
- 229960001138 acetylsalicylic acid Drugs 0.000 claims abstract description 188
- 238000012377 drug delivery Methods 0.000 claims abstract description 18
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 208000007536 Thrombosis Diseases 0.000 claims abstract description 14
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 28
- 238000011282 treatment Methods 0.000 claims description 26
- 208000005189 Embolism Diseases 0.000 claims description 25
- 208000001435 Thromboembolism Diseases 0.000 claims description 25
- 239000002105 nanoparticle Substances 0.000 claims description 15
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 239000001509 sodium citrate Substances 0.000 claims description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical group O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract description 63
- 238000012384 transportation and delivery Methods 0.000 abstract description 57
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract description 20
- 230000002685 pulmonary effect Effects 0.000 abstract description 7
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 abstract description 4
- 239000003814 drug Substances 0.000 description 81
- 229940079593 drug Drugs 0.000 description 70
- 238000005516 engineering process Methods 0.000 description 62
- 210000004072 lung Anatomy 0.000 description 50
- 229940112141 dry powder inhaler Drugs 0.000 description 44
- 239000000443 aerosol Substances 0.000 description 28
- 230000037396 body weight Effects 0.000 description 22
- 230000008021 deposition Effects 0.000 description 21
- 230000000694 effects Effects 0.000 description 20
- 238000010579 first pass effect Methods 0.000 description 16
- 210000002345 respiratory system Anatomy 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- 230000008901 benefit Effects 0.000 description 15
- 239000007788 liquid Substances 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- 238000009826 distribution Methods 0.000 description 13
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 13
- 230000001839 systemic circulation Effects 0.000 description 13
- 239000002775 capsule Substances 0.000 description 12
- 238000001694 spray drying Methods 0.000 description 12
- 239000007921 spray Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 230000000241 respiratory effect Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 229940124597 therapeutic agent Drugs 0.000 description 10
- 230000002776 aggregation Effects 0.000 description 9
- 210000003038 endothelium Anatomy 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 238000011084 recovery Methods 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 239000006185 dispersion Substances 0.000 description 8
- 239000007789 gas Substances 0.000 description 8
- 230000002503 metabolic effect Effects 0.000 description 8
- 210000000214 mouth Anatomy 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 208000024172 Cardiovascular disease Diseases 0.000 description 7
- 238000004220 aggregation Methods 0.000 description 7
- 239000006227 byproduct Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000010419 fine particle Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000008263 liquid aerosol Substances 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 208000010125 myocardial infarction Diseases 0.000 description 7
- 230000036470 plasma concentration Effects 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 239000006199 nebulizer Substances 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 6
- 229960001860 salicylate Drugs 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 6
- 229960004889 salicylic acid Drugs 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 208000006011 Stroke Diseases 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 238000000227 grinding Methods 0.000 description 5
- 238000011221 initial treatment Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 210000003800 pharynx Anatomy 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000011321 prophylaxis Methods 0.000 description 5
- 206010051055 Deep vein thrombosis Diseases 0.000 description 4
- 102100038199 Desmoplakin Human genes 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 206010037437 Pulmonary thrombosis Diseases 0.000 description 4
- 206010047249 Venous thrombosis Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 239000003125 aqueous solvent Substances 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 208000034158 bleeding Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000002664 inhalation therapy Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- 206010008132 Cerebral thrombosis Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 101000919849 Homo sapiens Cytochrome c oxidase subunit 1 Proteins 0.000 description 3
- 101000605122 Homo sapiens Prostaglandin G/H synthase 1 Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000003123 bronchiole Anatomy 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000005498 polishing Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000008337 systemic blood flow Effects 0.000 description 3
- 210000003437 trachea Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 229960004676 antithrombotic agent Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000002716 delivery method Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003434 inspiratory effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229940071648 metered dose inhaler Drugs 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 210000003300 oropharynx Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 210000001147 pulmonary artery Anatomy 0.000 description 2
- 210000003492 pulmonary vein Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 238000000935 solvent evaporation Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 2
- 229960000707 tobramycin Drugs 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OTJFTZJLQGKXCI-UHFFFAOYSA-N 2-acetyloxybenzoic acid;2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1O.CC(=O)OC1=CC=CC=C1C(O)=O OTJFTZJLQGKXCI-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101100136727 Caenorhabditis elegans psd-1 gene Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010014476 Elevated cholesterol Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000950638 Symphysodon discus Species 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 229940068372 acetyl salicylate Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000012387 aerosolization Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 230000006502 antiplatelets effects Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000007787 electrohydrodynamic spraying Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000004442 gravimetric analysis Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- HOQADATXFBOEGG-UHFFFAOYSA-N isofenphos Chemical compound CCOP(=S)(NC(C)C)OC1=CC=CC=C1C(=O)OC(C)C HOQADATXFBOEGG-UHFFFAOYSA-N 0.000 description 1
- 208000030175 lameness Diseases 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 229940066294 lung surfactant Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 238000007709 nanocrystallization Methods 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940086319 nattokinase Drugs 0.000 description 1
- 108010073682 nattokinase Proteins 0.000 description 1
- 235000013557 nattō Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000002399 phagocytotic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940020573 plavix Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 238000012383 pulmonary drug delivery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000006441 vascular event Effects 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
この出願は、2013年4月30日付で出願された米国仮出願第61/817,435号の利益を主張し、この参照によりその全体が組み込まれる。
血栓塞栓性の兆候および事象
血栓塞栓症、例えば、心筋梗塞、深部静脈血栓症、肺血栓症、脳血栓症等は、患者または臨床医が、前記イベントについての初期治療または処置を提供するのを可能にする特定の兆候を提供し得る。一部の状況では、81mgの低用量または低用量(baby)のアスピリンまたは通常のアスピリン(330mg)が、患者の初期処置を提供するために、経口投与される場合がある。
薬剤は、種々の方法、例えば、液体、カプセル、錠剤またはチュアブル錠において、経口投与され得る。ほとんどの場合、前記経口経路が使用される。最も都合がよく、最も安全で、最も安価であるためである。ただし、経口薬剤送達は、薬剤が典型的に消化管を通って移動する方法であるため限界を有する。
アスピリンは、サリチル酸のアセチル化型であり、アスピリンにおける活性な化学は、アセチルサリチル酸(ASA)と呼ばれる。アスピリンは、多数の人々により使用されて、所望の効果を達成しており、多くの人々により、低用量アスピリンが、多くの場合、毎日使用されている。アスピリンの原理的作用は、シクロオキシゲナーゼ酵素(具体的には、COX1およびCOX2の酵素)の機能を障害することである。
上記されたように、アスピリンの経口送達は、疼痛、消化不良をもたらす胃壁に対する傷害のリスクおよび出血の高いリスクを生じさせる場合がある。さらに、本願明細書に記載された実施形態の少なくとも1つの態様に基づいて、血栓塞栓症に関係するか、または、血栓塞栓症をもたらし得る緊急事態中に、多くの場合、薬剤を経口投与するのが困難であると認識される。例えば、患者は、嘔吐を起こすか、またはそうでなければ経口的に薬剤を摂取できない場合がある。さらに、薬剤の経口投与は、薬剤が直ちに全身性血流に達さないため、薬剤の重要な作用が遅延するために、望ましくない場合がある。全身性血流に達したとしても、肝臓および消化管における初回通過効果のために、全身性循環に達する薬剤量は、投与量より非常に少なくなる。したがって、本願明細書に開示された種々の実施形態の態様に基づいて、投与の代替経路は、これらの望ましくない副作用を避け得ると認識される。
ここで使用する場合、「約」の用語は、+/−5%の値を意味する。
NSAIDs、例えば、アスピリンは、種々の有益な効果を提供し、心血管疾患(例えば血栓症)のリスクを低下させるのに寄与する。しかしながら、臨床設定におけるNSAIDs、例えば、アスピリンの使用は、伝統的には、経口投与に限定されてきた。アスピリンの経口投与は、例えば、消化管および肝臓における初回通過効果により、経口用量の約2/3の損失または不活性化をもたらし得る。一方、前記用量の1/3は、全身性血流に達し、所望の作用を提供し、十分な用量により生じるネガティブな副作用により、多くの場合、患者が定期的または毎日アスピリンを使用するのを妨げる。
主題となる技術は、活性成分として、NSAID、例えば、アセチルサリチル酸を有する吸入用乾燥粉末および乾燥粒子に関する。
本願明細書に開示された一部の実施形態を通して、出願人は、従来の教示により認識されている課題を克服した。特に、出願人は、薬剤が肺に吸入された場合、前記薬剤が肺胞に向かって分散され得ることを認識した。肺胞は、主に、二酸化炭素を酸素に交換するのに機能し、肺胞は、酵素も産生する。このため、吸入された物質、例えば、病原体、薬剤または他の化学物質は、肺胞で処理され得る。
吸入用乾燥粒子および乾燥粉末は、任意の適切な方法を使用して調製され得る。吸入用乾燥粉末および粒子を調製するための多くの適切な方法が、当該分野において従来からあり、単独および二重の乳化溶媒蒸発法、スプレー乾燥、粉砕(例えば、ジェット粉砕)、ブレンド、溶媒抽出、溶媒蒸発、相分離、単独および複雑なコアセルベーション、界面重合、超臨界二酸化炭素(CO2)の使用を含む適切な方法ならびに他の適切な方法を含む。吸入用乾燥粒子は、当該分野において公知のマイクロスフェアまたはマイクロカプセルを調製するための方法を使用して調製され得る。これらの方法は、所望の空気力学的特性(例えば、空気力学的直径および幾何学的直径)を有する吸入用乾燥粒子の形成をもたらす条件下で使用され得る。必要に応じて、所望の特性、例えば、サイズおよび密度を有する吸入用乾燥粒子は、適切な方法、例えば、ふるい分けを使用して選択され得る。
他の態様では、主題となる技術は、心血管疾患(例えば、血栓症)を処置(例えば、予防的処置またはリスクの低下)するための方法であって、それを必要とする対象の気道に、有効量の本願明細書に記載された吸入用乾燥粒子または乾燥粉末を投与することを有する方法である。
Claims (23)
- アセチルサリチル酸またはその薬学的に許容され得る塩を有する吸入用乾燥粒子を有する吸入用乾燥粉末であって、
前記乾燥粉末は、(i)約5μm以下の体積メジアン幾何学的直径(VMGD)を有する乾燥粒子と、(ii)約15μm以上の体積メジアン幾何学的直径(VMGD)を有する乾燥粒子との混合物を有する、吸入用乾燥粉末。 - 請求項1記載の吸入用乾燥粉末において、少なくとも50%の前記乾燥粒子は、約5μm以下の体積メジアン幾何学的直径(VMGD)を有する、吸入用乾燥粉末。
- 請求項1または2記載の吸入用乾燥粉末において、少なくとも70%の前記乾燥粒子は、約5μm以下の体積メジアン幾何学的直径(VMGD)を有する、吸入用乾燥粉末。
- アセチルサリチル酸またはその薬学的に許容され得る塩を有する吸入用乾燥粒子を有する吸入用乾燥粉末であって、
前記乾燥粉末は、(i)約5μm以下の質量メジアン空気力学的直径(MMAD)を有する乾燥粒子と、(ii)約15μm以上の質量メジアン空気力学的直径(MMAD)を有する乾燥粒子との混合物を有する、吸入用乾燥粉末。 - 請求項1記載の吸入用乾燥粉末において、少なくとも50%の前記乾燥粒子は、約5μm以下の質量メジアン空気力学的直径(MMAD)を有する、吸入用乾燥粉末。
- 請求項1または2記載の吸入用乾燥粉末において、少なくとも70%の前記乾燥粒子は、約5μm以下の質量メジアン空気力学的直径(MMAD)を有する、吸入用乾燥粉末。
- 請求項1〜6のいずれか一項に記載の吸入用乾燥粉末において、前記乾燥粉末は、賦形剤を有さない、吸入用乾燥粉末。
- 請求項1〜7のいずれか一項に記載の吸入用乾燥粉末において、前記乾燥粉末は、ナノ粒子の凝集体を有し、前記ナノ粒子の平均径は、約5nmから約500nmである、吸入用乾燥粉末。
- 請求項8記載の吸入用乾燥粉末において、前記ナノ粒子は、約1μmから約25μmの体積メジアン幾何学的直径(VMGD)を有する中空の凝集体を形成する、吸入用乾燥粉末。
- 血栓症を治療するための薬剤送達システムであって、前記システムは、請求項1〜9のいずれか一項に記載の吸入用乾燥粉末を有し、アセチルサリチル酸は、約40mg以下の用量で存在する、薬剤送達システム。
- 請求項10記載の薬剤送達システムにおいて、アセチルサリチル酸は、約40mg以下の用量で存在する、薬剤送達システム。
- 血栓症を治療し、または血栓塞栓症のリスクを低下させる方法であって、
それを必要とする対象に、治療的に有効量のアセチルサリチル酸を投与する工程を有し、前記アセチルサリチル酸は、請求項1〜9のいずれか一項に記載の吸入用乾燥粉末を有する乾燥粉末吸入器によって送達され、前記対象に投与されるアセチルサリチル酸の用量は、約40mg以下である、方法。 - 請求項12記載の方法において、アセチルサリチル酸は、約40mg以下の用量で存在する、方法。
- アセチルサリチル酸またはその薬学的に許容され得る塩を有する吸入用乾燥粒子を有する吸入用乾燥粉末であって、
前記吸入用乾燥粒子は、約10μm以下の体積メジアン幾何学的直径(VMGD)を有する、吸入用乾燥粉末。 - 請求項14記載の吸入用乾燥粉末において、前記吸入用乾燥粒子は、約5.0μm以下の体積メジアン幾何学的直径(VMGD)を有する、吸入用乾燥粉末。
- アセチルサリチル酸またはその薬学的に許容され得る塩を有する吸入用乾燥粒子を有する吸入用乾燥粉末であって、
前記吸入用乾燥粒子は、約10μm以下の質量メジアン空気力学的直径(MMAD)を有する、吸入用乾燥粉末。 - 請求項16記載の吸入用乾燥粉末において、前記吸入用乾燥粒子は、約5.0μm以下の質量メジアン空気力学的直径(MMAD)を有する、吸入用乾燥粉末。
- 薬学的に許容され得る賦形剤によって実質的に封入されている、アセチルサリチル酸またはその薬学的に許容され得る塩を有する吸入用乾燥粒子を有する吸入用乾燥粉末であって、
前記吸入用乾燥粒子は、約10μm以下の体積メジアン幾何学的直径(VMGD)を有する、吸入用乾燥粉末。 - 薬学的に許容され得る賦形剤によって実質的に封入されている、アセチルサリチル酸またはその薬学的に許容され得る塩を有する吸入用乾燥粒子を有する吸入用乾燥粉末であって、
前記吸入用乾燥粒子は、約10μm以下の質量メジアン空気力学的直径(MMAD)を有する、吸入用乾燥粉末。 - 請求項18または19記載の吸入用乾燥粉末において、約25%から約50%(重量パーセント)の前記乾燥粉末は、アセチルサリチル酸である、吸入用乾燥粉末。
- 請求項18〜20のいずれか一項に記載の吸入用乾燥粉末において、前記賦形剤は、クエン酸ナトリウムまたはラクトースである、吸入用乾燥粉末。
- 血栓症を治療するための薬剤送達システムであって、
前記システムは、請求項14〜21のいずれか一項に記載の吸入用乾燥粉末を有し、アセチルサリチル酸は、約40mg以下の用量で存在する、薬剤送達システム。 - 血栓症を治療する方法であって、
それを必要とする対象に、治療的に有効量のアセチルサリチル酸を投与する工程を有し、前記アセチルサリチル酸は、請求項14〜21のいずれか一項に記載の吸入用乾燥粉末を有する乾燥粉末吸入器によって送達され、前記対象に投与されるアセチルサリチル酸の用量は、約40mg以下である、方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023062960A JP2023086774A (ja) | 2013-04-30 | 2023-04-07 | 乾燥粉末配合および使用方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361817435P | 2013-04-30 | 2013-04-30 | |
US61/817,435 | 2013-04-30 | ||
JP2019034152A JP2019089843A (ja) | 2013-04-30 | 2019-02-27 | 乾燥粉末配合および使用方法 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019034152A Division JP2019089843A (ja) | 2013-04-30 | 2019-02-27 | 乾燥粉末配合および使用方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023062960A Division JP2023086774A (ja) | 2013-04-30 | 2023-04-07 | 乾燥粉末配合および使用方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2021102620A true JP2021102620A (ja) | 2021-07-15 |
Family
ID=48917722
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016511717A Pending JP2016518388A (ja) | 2013-04-30 | 2013-07-24 | 乾燥粉末配合および使用方法 |
JP2019034152A Pending JP2019089843A (ja) | 2013-04-30 | 2019-02-27 | 乾燥粉末配合および使用方法 |
JP2021035890A Pending JP2021102620A (ja) | 2013-04-30 | 2021-03-06 | 乾燥粉末配合および使用方法 |
JP2023062960A Pending JP2023086774A (ja) | 2013-04-30 | 2023-04-07 | 乾燥粉末配合および使用方法 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016511717A Pending JP2016518388A (ja) | 2013-04-30 | 2013-07-24 | 乾燥粉末配合および使用方法 |
JP2019034152A Pending JP2019089843A (ja) | 2013-04-30 | 2019-02-27 | 乾燥粉末配合および使用方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023062960A Pending JP2023086774A (ja) | 2013-04-30 | 2023-04-07 | 乾燥粉末配合および使用方法 |
Country Status (8)
Country | Link |
---|---|
US (3) | US10149823B2 (ja) |
EP (2) | EP3607941A1 (ja) |
JP (4) | JP2016518388A (ja) |
CN (1) | CN105473133A (ja) |
AU (1) | AU2013388034B2 (ja) |
CA (1) | CA2910766C (ja) |
HK (2) | HK1218720A1 (ja) |
WO (1) | WO2014178891A1 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
EP3607941A1 (en) | 2013-04-30 | 2020-02-12 | Otitopic Inc. | Dry powder formulations and methods of use |
PL3107548T3 (pl) | 2014-02-20 | 2022-10-31 | Otitopic Inc. | Suche formulacje w proszku do inhalacji |
KR102666667B1 (ko) | 2014-07-31 | 2024-05-17 | 벡추라 인코포레이티드 | 흡입용 건조 분말 제형 |
WO2017100656A1 (en) * | 2015-12-11 | 2017-06-15 | Otitopic Inc. | Dry powder formulations of aspirin for inhalation |
CA3001962C (en) * | 2015-12-22 | 2022-09-13 | Ventaleon Gmbh | Treatment of moderate to severe influenza |
WO2017210658A1 (en) * | 2016-06-03 | 2017-12-07 | Otitopic Inc. | Dry powder formulations for inhalation |
WO2018222583A1 (en) | 2017-05-30 | 2018-12-06 | Rho Pharmaceuticals, Llc | In-vial deposition of a stable, sterile and crystalline o-acetyl salicylic acid (aspirin) |
AU2017432640B2 (en) | 2017-09-22 | 2023-11-30 | Vectura Inc. | Dry powder compositions with magnesium stearate |
US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
US11844792B2 (en) | 2020-07-10 | 2023-12-19 | Sean Downing | Treatment for severe acute respiratory illness associated with coronavirus |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003512431A (ja) * | 1999-10-22 | 2003-04-02 | ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト | フィブリン依存型微小循環障害の治療及び予防のための医薬品の製造におけるジピリダモール又はモピダモールの使用 |
JP2004509141A (ja) * | 2000-09-19 | 2004-03-25 | アドバンスト インハレーション リサーチ,インコーポレイテッド | 中枢神経系の障害の処置における肺送達 |
JP2008505126A (ja) * | 2004-07-07 | 2008-02-21 | メディキュア インターナショナル インコーポレイテッド | 血小板凝集薬を用いる併用療法 |
US20120145150A1 (en) * | 2010-12-07 | 2012-06-14 | Respira Therapeutics, Inc. | Dry powder inhaler |
Family Cites Families (216)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2293359A (en) * | 1941-01-08 | 1942-08-18 | Quisling Sverre | Acetyl salicylic acid preparation |
FR2224175B1 (ja) | 1973-04-04 | 1978-04-14 | Isf Spa | |
US4069819A (en) | 1973-04-13 | 1978-01-24 | Societa Farmaceutici S.P.A. | Inhalation device |
BR8007911A (pt) | 1979-12-06 | 1981-06-16 | Glaxo Group Ltd | Inalador aperfeicoado |
US4375468A (en) | 1981-07-13 | 1983-03-01 | Verex Laboratories, Inc. | Constant order release aspirin composition and method of treating arthritis |
US4885287A (en) | 1988-08-09 | 1989-12-05 | University Of Kentucky Research Foundation | Novel method of administering aspirin and dosage forms containing same |
US5511726A (en) | 1988-09-23 | 1996-04-30 | Battelle Memorial Institute | Nebulizer device |
IT1228459B (it) | 1989-02-23 | 1991-06-19 | Phidea S R L | Inalatore con svuotamento regolare e completo della capsula. |
EP0499142A3 (en) | 1991-02-09 | 1993-05-05 | Hoechst Aktiengesellschaft | Potentiation of the antireactive-antiasthmatic effect of inhaled loop diuretics by inhaled non steroidal anti-flammatory drugs |
DE69229070T2 (de) * | 1991-02-09 | 1999-11-18 | B S D Bio Science Dev Snc Di O | Antireaktive antiasthmatische Wirkung von Acetylsalicylsäure durch Inhalation |
US5256538A (en) * | 1991-03-08 | 1993-10-26 | Board Of Regents, The University Of Texas System | Detection of early platelet activation and prediagnosis of thrombotic events |
US5993805A (en) | 1991-04-10 | 1999-11-30 | Quadrant Healthcare (Uk) Limited | Spray-dried microparticles and their use as therapeutic vehicles |
US5327883A (en) | 1991-05-20 | 1994-07-12 | Dura Pharmaceuticals, Inc. | Apparatus for aerosolizing powdered medicine and process and using |
GB2291605B (en) | 1991-11-12 | 1996-05-01 | Medix Ltd | A nebuliser and nebuliser control system |
US5639441A (en) | 1992-03-06 | 1997-06-17 | Board Of Regents Of University Of Colorado | Methods for fine particle formation |
US6098620A (en) | 1993-01-29 | 2000-08-08 | Aradigm Corporation | Device for aerosolizing narcotics |
US5724957A (en) | 1993-01-29 | 1998-03-10 | Aradigm Corporation | Intrapulmonary delivery of narcotics |
US20070117863A1 (en) | 1993-02-22 | 2007-05-24 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
TW402506B (en) | 1993-06-24 | 2000-08-21 | Astra Ab | Therapeutic preparation for inhalation |
US5506203C1 (en) | 1993-06-24 | 2001-02-06 | Astra Ab | Systemic administration of a therapeutic preparation |
GB9322014D0 (en) * | 1993-10-26 | 1993-12-15 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
PT101450B (pt) | 1994-02-02 | 1999-11-30 | Hovione Produtos Farmaceuticos | Novo dispositivo para inalacao |
US6051256A (en) | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
US6290991B1 (en) | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
HU219899B (hu) | 1995-04-14 | 2001-09-28 | Glaxo Wellcome Inc. | Inhalálóberendezés flutikaszon-propionát adagolására mért dózisban |
KR19980703876A (ko) | 1995-04-14 | 1998-12-05 | 스티븐 엘. 허스트 | 분산성이 개선된 분말화된 약학적 조성물 |
US6209538B1 (en) | 1995-08-02 | 2001-04-03 | Robert A. Casper | Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament |
US5875776A (en) | 1996-04-09 | 1999-03-02 | Vivorx Pharmaceuticals, Inc. | Dry powder inhaler |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US6503480B1 (en) | 1997-05-23 | 2003-01-07 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US6652837B1 (en) | 1996-05-24 | 2003-11-25 | Massachusetts Institute Of Technology | Preparation of novel particles for inhalation |
US6254854B1 (en) | 1996-05-24 | 2001-07-03 | The Penn Research Foundation | Porous particles for deep lung delivery |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
US20010031244A1 (en) | 1997-06-13 | 2001-10-18 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
DE69814428T2 (de) | 1997-09-29 | 2004-05-13 | Nektar Therapeutics, San Carlos | In verneblern verwendbare, stabilisierte zubereitungen |
US6433040B1 (en) | 1997-09-29 | 2002-08-13 | Inhale Therapeutic Systems, Inc. | Stabilized bioactive preparations and methods of use |
US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
US6309623B1 (en) | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
GB9807232D0 (en) | 1998-04-03 | 1998-06-03 | Univ Cardiff | Aerosol composition |
US6284282B1 (en) | 1998-04-29 | 2001-09-04 | Genentech, Inc. | Method of spray freeze drying proteins for pharmaceutical administration |
WO2000000215A1 (en) | 1998-06-29 | 2000-01-06 | Inhale Therapeutic Systems, Inc. | Particulate delivery systems and methods of use |
GB9814172D0 (en) | 1998-06-30 | 1998-08-26 | Andaris Ltd | Formulation for inhalation |
IL143046A0 (en) | 1998-11-12 | 2002-04-21 | Pilkiewicz Frank G | An inhalation system |
US7521068B2 (en) | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
JP3739955B2 (ja) | 1999-01-11 | 2006-01-25 | 株式会社日立製作所 | 吸入式投薬器 |
US6630169B1 (en) | 1999-03-31 | 2003-10-07 | Nektar Therapeutics | Particulate delivery systems and methods of use |
US7919119B2 (en) | 1999-05-27 | 2011-04-05 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US6858199B1 (en) | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
DE60012347T2 (de) | 1999-10-12 | 2005-07-28 | Shl Medical Ab | Inhalator |
US20030176421A1 (en) | 1999-12-30 | 2003-09-18 | Watson John W. | Prokinetic agents for treating gastric hypomotility and related disorders |
EP1941868A3 (en) | 2000-02-28 | 2011-06-29 | PharmaKodex Limited | Improvements in or relating to the delivery of oral drugs |
US6998137B2 (en) | 2000-04-07 | 2006-02-14 | Macromed, Inc. | Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix |
GB0009469D0 (en) | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formalities for use in inhaler devices |
PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
GB0010709D0 (en) | 2000-05-03 | 2000-06-28 | Vectura Ltd | Powders for use a in dry powder inhaler |
EP1177805A1 (en) | 2000-07-31 | 2002-02-06 | Maryland Financial Inc. | Powder inhaler |
FR2812545B1 (fr) | 2000-08-03 | 2003-03-28 | Air Liquide Sante Int | Aerosol medicamenteux inhalable dans le traitement ou la prevention de la douceur |
JP2004515467A (ja) | 2000-08-07 | 2004-05-27 | ネクター セラピューティックス | 吸入可能な、噴霧乾燥した、最少の凝集物を有する4−ヘリックスバンドルタンパク質粉末 |
US20020025917A1 (en) | 2000-08-28 | 2002-02-28 | Edward Pappalardo | Compartmentalized device to enable a process of liquefying and administering aspirin as a first aid to heart attack victims |
FI20002215A0 (fi) | 2000-10-06 | 2000-10-06 | Orion Yhtymae Oyj | Yhdistelmäpartikkelit |
CA2429773A1 (en) | 2000-12-22 | 2002-07-04 | Aspen Aerogels, Inc. | Aerogel powder comprising therapeutic agents |
KR100692934B1 (ko) | 2000-12-25 | 2007-03-12 | 상꾜 가부시키가이샤 | 아스피린을 함유하는 의약 조성물 |
DE60101451T2 (de) | 2001-03-05 | 2004-10-21 | Pera Ivo E | Inhaliergerät zur Verteilung von in einer Kapsel enthaltenen Medikamenten in Pulverform durch die Atemwege |
US20060293217A1 (en) | 2001-03-19 | 2006-12-28 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained release |
US6766799B2 (en) | 2001-04-16 | 2004-07-27 | Advanced Inhalation Research, Inc. | Inhalation device |
US6848197B2 (en) * | 2001-04-18 | 2005-02-01 | Advanced Inhalation Research, Inc. | Control of process humidity to produce large, porous particles |
US6455028B1 (en) | 2001-04-23 | 2002-09-24 | Pharmascience | Ipratropium formulation for pulmonary inhalation |
US20040049022A1 (en) | 2001-04-24 | 2004-03-11 | Nyce Jonathan W. | Composition & methods for treatment and screening |
CA2446904A1 (en) | 2001-05-24 | 2003-04-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
WO2003043585A2 (en) | 2001-11-20 | 2003-05-30 | Advanced Inhalation Research, Inc. | Improved particulate compositions for pulmonary delivery |
GB0129270D0 (en) | 2001-12-06 | 2002-01-23 | Pfizer Ltd | Pharmaceutical combination |
GB0129397D0 (en) | 2001-12-07 | 2002-01-30 | Pfizer Ltd | Pharmaceutical combination |
ITMI20020078A1 (it) | 2002-01-16 | 2003-07-16 | Fabrizio Niccolai | Dispositivo utilizzabile nel tratamento di affezzioni delle vie respiratorie |
WO2003072080A1 (en) | 2002-02-22 | 2003-09-04 | Advanced Inhalation Research, Inc. | Inhalable formulations for sustained release |
SE524990C2 (sv) | 2002-04-12 | 2004-11-09 | Microdrug Ag | Preparation av terapeutiskt torrt pulver samt förfarande för uppdelning och spridning i luft av medicinskt pulver |
US7405207B2 (en) | 2002-06-17 | 2008-07-29 | Epigenesis Pharmaceuticals, Inc. | Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof |
AU2003276131A1 (en) | 2002-06-18 | 2003-12-31 | Epigenesis Pharmaceuticals, Inc. | A dry powder oligonucleotide formulation, preparation and its uses |
CA2500065A1 (en) | 2002-09-30 | 2004-04-15 | Acusphere, Inc. | Sustained release porous microparticles for inhalation |
GB0226105D0 (en) | 2002-11-08 | 2002-12-18 | St Georges S Entpr Ltd | Pain relief agents |
US7516741B2 (en) | 2002-12-06 | 2009-04-14 | Novartis Ag | Aerosolization apparatus with feedback mechanism |
US7284553B2 (en) | 2002-12-12 | 2007-10-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powder inhaler comprising a chamber for a capsule for taking up a non-returnable capsule being filled with an active ingredient |
SE0203687D0 (sv) | 2002-12-13 | 2002-12-13 | Ian Harwigsson Med Adagit Fa | Pharmaceutical Porous Particles |
US20040206350A1 (en) | 2002-12-19 | 2004-10-21 | Nektar Therapeutics | Aerosolization apparatus with non-circular aerosolization chamber |
US7669596B2 (en) | 2002-12-31 | 2010-03-02 | Novartis Pharma Ag | Aerosolization apparatus with rotating capsule |
US7878193B2 (en) | 2003-01-14 | 2011-02-01 | Boehringer Ingelheim International Gmbh | Capsule for taking an active substance which can be inhaled |
CA2521394A1 (en) | 2003-04-09 | 2004-10-28 | Wyeth | Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.o]non-1 (7)-en-2-yl)alkyl] phosphonic acid and derivatives and methods of use thereof |
MXPA05010842A (es) | 2003-04-09 | 2006-03-30 | Nektar Therapeutics | Aparato de nebulizacion con protector de entrada de aire. |
DK1615689T3 (da) | 2003-04-09 | 2016-03-14 | Novartis Ag | Apparatur til dannelse af en aerosol og omfattende en opretningsføring til punktering af en kapsel |
GB0312419D0 (en) | 2003-05-30 | 2003-07-02 | Boots Healthcare Int Ltd | Use of a compound in the treatment of sleep disorders and the like, in providing refreshedness on waking and a method for the treatment of grogginess |
AU2004249166B2 (en) | 2003-06-13 | 2008-10-09 | Alkermes, Inc. | Low dose pharmaceutical powders for inhalation |
SE527069C2 (sv) | 2003-06-19 | 2005-12-13 | Mederio Ag | Förfarande och anordning för administrering av läkemedelspulver |
SG135204A1 (en) | 2003-07-18 | 2007-09-28 | Baxter Int | Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation |
EP1660428A1 (en) | 2003-08-20 | 2006-05-31 | Eli Lilly And Company | Ppar modulators |
WO2005018624A2 (en) | 2003-08-22 | 2005-03-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Methods of treating copd and pulmonary hypertension |
US20050249697A1 (en) | 2003-09-24 | 2005-11-10 | Uhrich Kathryn E | Compositions and methods for the inhibition of bone growth and resorption |
GB2407040B (en) | 2003-10-15 | 2007-09-19 | Sheikh Arshad Saeed | Anti-platelet aggregation compositions |
WO2005040163A1 (en) | 2003-10-28 | 2005-05-06 | Dr. Reddy's Laboratories Ltd | Heterocyclic compounds that block the effects of advanced glycation end products (age) |
WO2005041886A2 (en) | 2003-10-31 | 2005-05-12 | Metaphore Pharmaceuticals, Inc. | Methods for generating or increasing revenues related to pain inhibitor commerce |
WO2005079234A2 (en) | 2004-02-05 | 2005-09-01 | Etienne-Emile Baulieu | Treatment of pulmonary artery hypertension with dhea, dheas, dhea analogs or dhea derivatives |
US20050187268A1 (en) | 2004-02-23 | 2005-08-25 | Prolexys Pharmaceuticals Inc. | Non-peptidyl agents with pHSP20-like activity, and uses thereof |
AU2005237523A1 (en) | 2004-04-23 | 2005-11-10 | Cydex Pharmaceuticals, Inc. | DPI formulation containing sulfoalkyl ether cyclodextrin |
WO2005105732A1 (en) | 2004-05-04 | 2005-11-10 | Pfizer Japan Inc. | Substituted methyl aryl or heteroaryl amide compounds |
US7968575B2 (en) | 2004-05-05 | 2011-06-28 | Renopharm Ltd. | Nitric oxide donors and uses thereof |
US7189750B2 (en) | 2004-05-05 | 2007-03-13 | Renopharm Ltd. | Thiazole-based nitric oxide donors having at least two thiazole moieties and uses thereof |
RU2006143544A (ru) | 2004-05-10 | 2008-06-20 | Нэстек Фармасьютикал Кампани Инк. (Us) | Композиции и способ для облегченной чресслизистой доставки паратиреоидного гормона |
US7556035B2 (en) | 2004-05-28 | 2009-07-07 | Quadrant Technologies Limited | Unit dose dry powder inhaler |
WO2006017354A1 (en) | 2004-07-13 | 2006-02-16 | Pharmacofore, Inc. | Compositions of nicotinic agonists and therapeutic agents and methods for treating or preventing disease or pain |
MX2007001561A (es) | 2004-08-04 | 2007-04-16 | Schering Corp | Formulacion farmaceutica que comprende pleconaril para tratamiento de enfermedades de vias aereas. |
CN101031307B (zh) | 2004-11-02 | 2012-09-05 | 小利兰斯坦福大学托管委员会 | 抑制nkt细胞的制药用途 |
GB0425758D0 (en) * | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
ITMI20050417A1 (it) * | 2005-03-15 | 2006-09-16 | Medestea Res & Production S R L | Uso di farmaci anti-infiammatori non steroidei per via inalatoria nella terapia della bronchite acuta e cronica |
US20060249144A1 (en) | 2005-05-05 | 2006-11-09 | Pulmatrix Inc. | Ultrasonic Aerosol Generator |
TWI366460B (en) | 2005-06-16 | 2012-06-21 | Euro Celtique Sa | Cannabinoid active pharmaceutical ingredient for improved dosage forms |
EP1919939A2 (en) | 2005-07-27 | 2008-05-14 | Nastech Pharmaceutical Company Inc. | Tight junction modulating peptide components for enhancing mucosal delivery |
ITMI20051999A1 (it) | 2005-10-21 | 2007-04-22 | Eratech S R L | Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita' |
CA2631493A1 (en) | 2005-12-15 | 2007-06-21 | Acusphere, Inc. | Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration |
US7651770B2 (en) | 2005-12-16 | 2010-01-26 | The University Of Kansas | Nanoclusters for delivery of therapeutics |
WO2007072503A2 (en) | 2005-12-21 | 2007-06-28 | Panacea Biotec Ltd. | Combinations for managing inflammation and associated disorders |
US7201929B1 (en) | 2005-12-30 | 2007-04-10 | Alan James Group, Llc. | Aspirin formulation for cardiovascular health |
KR102180849B1 (ko) | 2006-01-24 | 2020-11-20 | 안선 바이오파르마, 아이엔씨. | 고분자 미소 구체들의 조제를 위한 기술 |
GB0605723D0 (en) | 2006-03-23 | 2006-05-03 | 3M Innovative Properties Co | Powder filling processes |
US7806117B2 (en) | 2006-06-07 | 2010-10-05 | Shin Nippon Biomedical Laboratories, Ltd. | Peroral powder delivery device |
US8201555B2 (en) | 2006-06-27 | 2012-06-19 | Brintech International Limited | Inhaler |
AU2007284690A1 (en) | 2006-08-10 | 2008-02-21 | Roy C. Levitt | Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors |
GB0617171D0 (en) | 2006-08-31 | 2006-10-11 | Generics Uk Ltd | Novel compositions and methods |
US20080063722A1 (en) * | 2006-09-08 | 2008-03-13 | Advanced Inhalation Research, Inc. | Composition of a Spray-Dried Powder for Pulmonary Delivery of a Long Acting Neuraminidase Inhibitor (LANI) |
US20080066739A1 (en) | 2006-09-20 | 2008-03-20 | Lemahieu Edward | Methods and systems of delivering medication via inhalation |
US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
GB0621957D0 (en) | 2006-11-03 | 2006-12-13 | Vectura Group Plc | Inhaler devices and bespoke pharmaceutical compositions |
NL1033047C2 (nl) | 2006-12-13 | 2008-06-16 | Pharmachemie Bv | Capsule, gevuld met een medicijn, in het bijzonder een inhaleerbaar medicijn. |
GB0625303D0 (en) | 2006-12-19 | 2007-01-24 | Jagotec Ag | Improvements in and relating to metered dose inhalers |
GB0700839D0 (en) | 2007-01-17 | 2007-02-21 | Braithwaite Philip | Device |
EP1964564A1 (en) | 2007-04-19 | 2008-09-03 | LAB International SRL | Breakthrough Pain Management |
US8530463B2 (en) | 2007-05-07 | 2013-09-10 | Hale Biopharma Ventures Llc | Multimodal particulate formulations |
AU2008266948B2 (en) | 2007-06-13 | 2012-08-23 | Kirin-Amgen, Inc. | IL-17 heteromeric receptor complex |
CA2693771A1 (en) | 2007-07-13 | 2009-01-22 | Abbott Biotechnology Ltd. | Methods and compositions for pulmonary administration of a tnf.alpha. inhibitor |
EP2173327A2 (en) | 2007-07-24 | 2010-04-14 | Nexbio, Inc. | Technology for the preparation of microparticles |
US9358242B2 (en) | 2007-08-30 | 2016-06-07 | Prelief Inc. | Calcium glycerophosphate for treating and preventing respiratory diseases or conditions |
RU2487730C2 (ru) | 2007-12-05 | 2013-07-20 | Новартис Аг | Емкость для лекарственного средства аэрозольного применения |
JP5767812B2 (ja) | 2007-12-06 | 2015-08-19 | バーグ リミテッド ライアビリティ カンパニー | 生物学的利用率が向上した吸入可能な組成物 |
AU2008345034A1 (en) | 2007-12-27 | 2009-07-09 | Aires Pharmaceuticals, Inc. | Aerosolized nitrite and nitric oxide - donating compounds and uses thereof |
DE102008004386A1 (de) | 2008-01-14 | 2009-07-23 | Activaero Gmbh | Verwendung eines Acetylsalicylsäuresalzes zur Behandlung viraler Infektionen |
MX2010007755A (es) | 2008-01-15 | 2010-12-21 | Univ Strasbourg | Sintesis de lactonas de acido resorcilico utiles como agentes terapeuticos. |
CN102037017B (zh) | 2008-02-21 | 2014-07-09 | 麒麟-安姆根有限公司 | Il-17ra-il-17rb拮抗物及其用途 |
GB0803369D0 (en) | 2008-02-25 | 2008-04-02 | Helperby Therapeutics Ltd | Biological materials and uses thereof |
CN102083817A (zh) | 2008-04-04 | 2011-06-01 | Irm责任有限公司 | 作为itpkb抑制剂的化合物和组合物 |
JP2011518155A (ja) | 2008-04-15 | 2011-06-23 | サーコード コーポレイション | 免疫関連障害の局所治療に使用するためのエアゾール化lfa−1アンタゴニスト |
MX2010012457A (es) | 2008-05-13 | 2010-12-07 | Irm Llc | Heterociclos que contienen nitrogeno fusionado y composiciones de los mismos como inhibidores de cinasa. |
US20110112134A1 (en) | 2008-05-16 | 2011-05-12 | Amira Pharmaceuticals, Inc. | Tricyclic Antagonists of Prostaglandin D2 Receptors |
EP2570147B1 (en) | 2008-06-13 | 2017-10-18 | MannKind Corporation | A dry powder inhaler and system for drug delivery |
RU2011101151A (ru) | 2008-07-15 | 2012-07-20 | Шеринг Корпорейшн (US) | Интраназальные композиции, содержащие деконгестант и кортикостероид |
BRPI0915803A2 (pt) | 2008-07-18 | 2015-11-10 | Prosonix Ltd | processo para aumentar a cristalinidade de pelo menos um material sólido, partícula, composição farmacêutica, e, inalador |
WO2010011329A2 (en) | 2008-07-23 | 2010-01-28 | Map Pharmaceuticals, Inc. | The delivery of powdered drug via inhalation |
US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
CA2734381A1 (en) | 2008-09-12 | 2010-03-18 | Critical Pharmaceuticals Limited | Improvements in the absorption of therapeutic agents across mucosal membranes or the skin |
PE20120647A1 (es) | 2009-03-13 | 2012-05-31 | Nucitec Sa De Cv | Composiciones y metodos para el tratamiento y prevencion de la enfermedad cardiovascular |
PT2410981T (pt) * | 2009-03-26 | 2017-05-25 | Pulmatrix Inc | Formulações em pó seco e métodos para tratar doenças pulmonares |
WO2010117951A1 (en) | 2009-04-06 | 2010-10-14 | The Regents Of The University Of California | Inhibitors of soluble epoxide hydrolase to inhibit or prevent niacin-induced flushing |
KR20130009577A (ko) | 2009-04-20 | 2013-01-23 | 오스펙스 파마슈티컬즈 엘엘씨 | 야누스 키나아제 3의 피페리딘 억제제 |
GB0908129D0 (en) | 2009-05-12 | 2009-06-24 | Innovata Ltd | Composition |
WO2010131486A1 (en) | 2009-05-15 | 2010-11-18 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal pharmaceutical compositions with improved pharmacokinetics |
US8985102B2 (en) | 2009-05-18 | 2015-03-24 | Adamis Pharmaceuticals Corporation | Dry powder inhalers |
US9125999B2 (en) | 2009-05-18 | 2015-09-08 | Adamis Pharmaceuticals Corporation | Dry powder inhaler dose counters |
US20120125325A1 (en) | 2009-06-01 | 2012-05-24 | Robin Mark Bannister | The use of amlexanox in the therapy of neutrophil-driven diseases |
GB201111485D0 (en) | 2011-07-05 | 2011-08-17 | Biocopea Ltd | Drug composition and its use in therapy |
GB0914231D0 (en) * | 2009-08-14 | 2009-09-30 | Breath Ltd | Dry powder inhaler formulations |
GB0917054D0 (en) | 2009-09-29 | 2009-11-11 | Cytoguide As | Agents, uses and methods |
TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
GB0918431D0 (en) | 2009-10-21 | 2009-12-09 | Prosonix Ltd | Process for improving crystallinity |
GB0921481D0 (en) | 2009-12-08 | 2010-01-20 | Vectura Ltd | Process and product |
SG184473A1 (en) | 2010-04-07 | 2012-11-29 | Abbvie Inc | Tnf-alpha binding proteins |
CN105640925B (zh) | 2010-08-30 | 2019-08-16 | 普马特里克斯营业公司 | 干燥粉末配方及用于治疗肺部疾病的方法 |
WO2012037665A1 (en) | 2010-09-24 | 2012-03-29 | Oral Delivery Technology Ltd. | Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions |
WO2012061902A1 (en) | 2010-11-12 | 2012-05-18 | Monash University | Micronised spray-dried particles comprising polymyxin |
CN102058886A (zh) | 2010-12-20 | 2011-05-18 | 云南白药集团无锡药业有限公司 | 医用粉雾剂及其应用 |
WO2012107364A1 (en) | 2011-02-07 | 2012-08-16 | Scipharm Sàrl | Novel composition for the treatment of cystic fibrosis |
GB201102237D0 (en) | 2011-02-09 | 2011-03-23 | Kuecept Ltd | Particle formulation |
JP6031510B2 (ja) | 2011-04-12 | 2016-11-24 | モイライ マトリックス インコーポレイテッド | 異常な線維芽細胞増殖及び細胞外マトリックスの沈着を特徴とする疾患、症状又はプロセスを予防又は治療する組成物及び方法 |
US8580853B2 (en) * | 2011-06-13 | 2013-11-12 | Howard PHYKITT | Analgesic composition and method of making the same |
MX351781B (es) | 2011-06-17 | 2017-10-30 | Berg Llc | Composiciones farmaceuticas inhalables. |
WO2013016220A1 (en) | 2011-07-22 | 2013-01-31 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
WO2013034910A1 (en) | 2011-09-06 | 2013-03-14 | Verona Pharma Plc | Inhalable compositions |
IN2014DN06108A (ja) | 2011-12-16 | 2015-08-14 | Indosys Ltd | |
JP2015505559A (ja) | 2012-01-31 | 2015-02-23 | セルリアン・ファーマ・インコーポレイテッド | 治療剤送達のためのシクロデキストリン系ポリマー |
SG10201703243QA (en) | 2012-02-28 | 2017-06-29 | Iceutica Holdings Inc | Inhalable pharmaceutical compositions |
NZ629722A (en) | 2012-02-29 | 2017-03-31 | Pulmatrix Operating Co Inc | Inhalable dry powders |
ES2625727T3 (es) | 2012-03-26 | 2017-07-20 | Arroyo Biosciences L.L.C. | Nuevos antagonistas de receptores de esfingosina-1-fosfato |
GB201205632D0 (en) | 2012-03-30 | 2012-05-16 | Vectura Ltd | Method and apparatus |
NZ742004A (en) | 2012-05-03 | 2019-04-26 | Kala Pharmaceuticals Inc | Pharmaceutical nanoparticles showing improved mucosal transport |
US10105500B2 (en) * | 2012-05-09 | 2018-10-23 | Virginia Commonwealth University | Dry powder inhaler (DPI) designs for producing aerosols with high fine particle fractions |
US9707228B2 (en) | 2012-05-21 | 2017-07-18 | Agency For Science, Technology And Research | Dry powder formulation |
JP6275707B2 (ja) | 2012-06-20 | 2018-02-07 | フランク・グー | 粘膜付着性ナノ粒子送達系 |
WO2014048065A1 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Triazolyl derivatives as syk inhibitors |
WO2014053482A1 (en) | 2012-10-03 | 2014-04-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the prophylactic treatment of bacterial superinfections post-influenza with invariant nkt cell agonists |
US20150284381A1 (en) | 2012-11-07 | 2015-10-08 | Merck Sharp & Dohme Corp. | Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors |
US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
SG11201505835QA (en) | 2013-01-28 | 2015-08-28 | Incozen Therapeutics Pvt Ltd | Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide |
TWI643853B (zh) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
GB201305813D0 (en) | 2013-03-28 | 2013-05-15 | Vectura Ltd | Compositions and methods |
EP3607941A1 (en) | 2013-04-30 | 2020-02-12 | Otitopic Inc. | Dry powder formulations and methods of use |
US9861608B2 (en) | 2013-05-23 | 2018-01-09 | Aztherapies, Inc | Methods for delivering cromolyn |
TWI641373B (zh) | 2013-07-25 | 2018-11-21 | 阿爾米雷爾有限公司 | 具有蕈毒鹼受體拮抗劑和β2腎上腺素受體促效劑二者之活性的2-胺基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽 |
CA2926793C (en) | 2013-10-11 | 2022-11-22 | Lawrence S. ZISMAN | Spray-dry formulations for treating pulmonary arterial hypertension |
PL3107548T3 (pl) * | 2014-02-20 | 2022-10-31 | Otitopic Inc. | Suche formulacje w proszku do inhalacji |
EP3653643A1 (en) | 2014-02-20 | 2020-05-20 | Allergan, Inc. | Complement component c5 antibodies |
SG11201606983SA (en) | 2014-02-27 | 2016-09-29 | Allergan Inc | COMPLEMENT FACTOR Bb ANTIBODIES |
CN106715443A (zh) | 2014-03-26 | 2017-05-24 | 坎格特生物技术制药有限责任公司 | Fl118母核化学结构平台产生用于治疗人类疾病的fl118衍生物的用途 |
EP3126004A4 (en) | 2014-04-02 | 2017-11-29 | Rogne Bioscience Inc. | Methods and compositions for treating inflammatory disorders |
WO2015155544A1 (en) | 2014-04-10 | 2015-10-15 | Patrick Crowley | Delivery of non-steroidal antiinflammatory agents to the brain via the nasal tract to treat neurological disorders |
WO2016176552A1 (en) * | 2015-04-30 | 2016-11-03 | Otitopic Inc. | Dry power formulations for inhalation |
WO2017210658A1 (en) * | 2016-06-03 | 2017-12-07 | Otitopic Inc. | Dry powder formulations for inhalation |
US10786456B2 (en) * | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
AU2017432640B2 (en) * | 2017-09-22 | 2023-11-30 | Vectura Inc. | Dry powder compositions with magnesium stearate |
-
2013
- 2013-07-24 EP EP19154878.3A patent/EP3607941A1/en active Pending
- 2013-07-24 JP JP2016511717A patent/JP2016518388A/ja active Pending
- 2013-07-24 AU AU2013388034A patent/AU2013388034B2/en active Active
- 2013-07-24 CA CA2910766A patent/CA2910766C/en active Active
- 2013-07-24 WO PCT/US2013/051895 patent/WO2014178891A1/en active Application Filing
- 2013-07-24 CN CN201380077562.XA patent/CN105473133A/zh active Pending
- 2013-07-24 EP EP13745533.3A patent/EP2991634A1/en not_active Withdrawn
- 2013-07-24 US US13/949,862 patent/US10149823B2/en active Active
-
2016
- 2016-06-13 HK HK16106773.2A patent/HK1218720A1/zh unknown
- 2016-06-14 HK HK16106840.1A patent/HK1218855A1/zh unknown
-
2018
- 2018-12-11 US US16/216,924 patent/US11865210B2/en active Active
-
2019
- 2019-02-27 JP JP2019034152A patent/JP2019089843A/ja active Pending
- 2019-04-26 US US16/396,272 patent/US11819569B2/en active Active
-
2021
- 2021-03-06 JP JP2021035890A patent/JP2021102620A/ja active Pending
-
2023
- 2023-04-07 JP JP2023062960A patent/JP2023086774A/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003512431A (ja) * | 1999-10-22 | 2003-04-02 | ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト | フィブリン依存型微小循環障害の治療及び予防のための医薬品の製造におけるジピリダモール又はモピダモールの使用 |
JP2004509141A (ja) * | 2000-09-19 | 2004-03-25 | アドバンスト インハレーション リサーチ,インコーポレイテッド | 中枢神経系の障害の処置における肺送達 |
JP2008505126A (ja) * | 2004-07-07 | 2008-02-21 | メディキュア インターナショナル インコーポレイテッド | 血小板凝集薬を用いる併用療法 |
US20120145150A1 (en) * | 2010-12-07 | 2012-06-14 | Respira Therapeutics, Inc. | Dry powder inhaler |
Non-Patent Citations (1)
Title |
---|
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 333, JPN6022012030, 2007, pages 187 - 198, ISSN: 0005057147 * |
Also Published As
Publication number | Publication date |
---|---|
CA2910766A1 (en) | 2014-11-06 |
JP2016518388A (ja) | 2016-06-23 |
US20190247304A1 (en) | 2019-08-15 |
CN105473133A (zh) | 2016-04-06 |
WO2014178891A1 (en) | 2014-11-06 |
JP2023086774A (ja) | 2023-06-22 |
EP2991634A1 (en) | 2016-03-09 |
US11819569B2 (en) | 2023-11-21 |
HK1218720A1 (zh) | 2017-03-10 |
HK1218855A1 (zh) | 2017-03-17 |
JP2019089843A (ja) | 2019-06-13 |
AU2013388034A1 (en) | 2015-11-12 |
US20140322328A1 (en) | 2014-10-30 |
US10149823B2 (en) | 2018-12-11 |
US11865210B2 (en) | 2024-01-09 |
EP3607941A1 (en) | 2020-02-12 |
CA2910766C (en) | 2020-12-15 |
AU2013388034B2 (en) | 2019-08-15 |
US20190105267A1 (en) | 2019-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021102620A (ja) | 乾燥粉末配合および使用方法 | |
JP6701086B2 (ja) | 吸入用の乾燥粉末製剤 | |
Javadzadeh et al. | Therapeutic nanostructures for pulmonary drug delivery | |
JP7493449B2 (ja) | ステアリン酸マグネシウムを含む乾燥粉末組成物 | |
AU2020203437B2 (en) | Dry powder formulations for inhalation | |
Pawar et al. | Insights of Dry Powder Inhaler: An Emerging Potential Drug Delivery with Novel Therapeutic Carriers | |
BR112017007142B1 (pt) | Composição farmacêutica para uso inalatório na forma de pó compreendendo budesonida e formoterol e kit compreendendo a referida composição |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210331 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20211117 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20211125 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220328 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220628 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220826 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20221207 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20230308 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230407 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20230407 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230418 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20230420 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20230519 |